Risultati della ricerca - Teresa Alonso Gordoa
- Mostra 1 - 20 risultati su 21
- Vai alla pagina seguente
-
1
GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours di Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande
Pubblicazione 2014Revisão -
2
Advances in thyroid cancer treatment: latest evidence and clinical potential di Teresa Alonso‐Gordoa, Juan J. Díez, Manuel Durán, Enrique Grande
Pubblicazione 2014Revisão -
3
-
4
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma di Pablo Álvarez Ballesteros, Jesús Chamorro, María San Román, Javier Pozas, V. Gómez Dos Santos, Álvaro Ruiz Granados, Enrique Grande, Teresa Alonso‐Gordoa, Javier Molina‐Cerrillo
Pubblicazione 2021Revisão -
5
-
6
-
7
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors di Sandip Pravin Patel, Teresa Alonso‐Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan Standifer, Doug Palmer, Lin‐Yang Cheng, Panagiotis Kourtesis, Maria Libera Ascierto, Mayukh Das, Jennifer R. Diamond, Matthew D. Hellmann, Benedito A. Carneiro
Pubblicazione 2024Artigo -
8
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer di Teresa Alonso‐Gordoa, Michael Goodman, Christof Vulsteke, Guilhem Roubaud, J. Zhang, Mamta Parikh, Josep M. Piulats, A. Ázaro, Gary D. James, Riccardo Cavazzina, Eric T. Gangl, Jeff Thompson, Gayle P. Pouliot, Rakesh Kumar, Christopher J. Sweeney
Pubblicazione 2024Artigo -
9
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma di Yohann Loriot, Cora N. Sternberg, Daniel Castellano, Sjoukje F. Oosting, Herlinde Dumez, Robert Huddart, Karina Vianna, Teresa Alonso Gordoa, Iwona Skoneczna, André P. Fay, Franco Nolé, Francesco Massari, Birutė Brasiūnienė, Pablo Maroto, Simon Fear, Flavia Di Nucci, Sabine de Ducla, Ernest Choy
Pubblicazione 2020Artigo -
10
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) di Enrique Grande, Jaume Capdevila, Daniel Castellano, Àlex Teulé, Ignacio Durán, Josep Fuster, Isabel Sevilla, P. Escudero, Javier Sastre, Jesús García-Donás, Oriol Casanovas, Julie Earl, Luís Ortega, María Apellániz-Ruiz, Cristina Rodríguez‐Antona, Teresa Alonso‐Gordoa, Juan J. Díez, Alfredo Carrato, Rocio García‐Carbonero
Pubblicazione 2015Artigo -
11
Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcin... di Yohann Loriot, Cora N. Sternberg, D. Castellano Gauna, Herlinde Dumez, Robert Huddart, Karina Vianna, Teresa Alonso Gordoa, Iwona Skoneczna, AP Fay, Cosimo Sacco, Franco Nolè, Francesco Massari, Birute Brasiūnienė, Pablo Maroto, Sjoukje F. Oosting, Simon Fear, Flavia Di Nucci, Sabine de Ducla, Ernest Choy
Pubblicazione 2019Artigo -
12
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Adva... di Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso‐Gordoa, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, Pablo Maroto, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frédéric Rolland, Mototsugu Oya, Karla Rodriguez-Lopez, Kenichi Saito, Jodi A. McKenzie, Camillo Porta
Pubblicazione 2023Artigo -
13
1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or l... di Jaume Capdevila, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Antonio Cubillo, Vicente Alonso, Teresa Alonso Gordoa, Alberto Carmona‐Bayonas, Guillermo Crespo, Montserrat Blanco-Codesido, Paula Jiménez‐Fonseca, A. Viúdez, Adelaida La Casta Muñoa, Isabel Sevilla, Marta Llanos, Ángel Segura, Jorge Hernando-Cubero, José Luís Manzano
Pubblicazione 2020Artigo -
14
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter... di María Carmen Riesco Martínez, Jaume Capdevila, Vicente Alonso, Paula Jiménez‐Fonseca, Àlex Teulé, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso‐Gordoa, Ana Custodio, Beatriz Antón-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo Trujillo, Arantza Lamas‐Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla, Rocio García‐Carbonero
Pubblicazione 2024Artigo -
15
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin di Jaume Capdevila, Jorge Hernando, Àlex Teulé, Carlos López, Rocio García‐Carbonero, Marta Benavent, Ana Custodio, Alejandro García‐Álvarez, Antonio Cubillo, Vicente Alonso, Alberto Carmona‐Bayonas, Teresa Alonso‐Gordoa, Guillermo Crespo, Paula Jiménez‐Fonseca, M. Blanco, A. Viúdez, Adelaida La Casta, Isabel Sevilla, Ángel Segura, Marta Llanos, Stefania Landolfi, Paolo Nucíforo, José Luís Manzano
Pubblicazione 2023Artigo -
16
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma di David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins
Pubblicazione 2021Artigo -
17
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study di Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca, Jorge Barriuso, Ángel Castaño, Marta Benavent, Vicente Alonso, María Carmen Riesco Martínez, Teresa Alonso‐Gordoa, Ana Custodio, Manuel Sánchez Cánovas, Jorge Hernando Cubero, Carlos López, Adelaida La Casta, Ana Fernández Montés, Mónica Marazuela, Guillermo Crespo, P. Escudero, José Ángel Díaz, E. Feliciangeli, Javier Gállego, Marta Llanos, Ángel Segura, F Vilardell, Juan Carlos Percovich, Enrique Grande, Jaume Capdevila, Juan W. Valle, Rocio García‐Carbonero
Pubblicazione 2019Artigo -
18
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study di Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, María T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Zin Myint, Giuseppe Fornarini, Thomas Büttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomáš Büchler, Hana Študentová, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni
Pubblicazione 2025Artigo -
19
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma di Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Pubblicazione 2021Artigo -
20
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study di María Isabel Del Olmo-García, Lorena Hernandez-Rienda, Rocio García‐Carbonero, Jorge Hernando, Ana Custodio, Beatriz Antón-Pascual, Marta Gómez, S. Palma-Milla, Lorena Suárez, Marta Bellver, Vicente Alonso, Raquel Serrano, Nuria Valdés, Marcos Melián, Beatríz Febrero, Miguel Sampedro‐Núñez, Josefina Biarnés, José Ángel Díaz-Pérez, Javier Molina‐Cerrillo, Carlos F. Lopez, Miguel Ángel Martínez Olmos, Juan Francisco Merino-Torres, Jaume Capdevila, María Argente, Paula Jiménez‐Fonseca, Teresa Alonso‐Gordoa, Alvaro Ruiz Grandos, Noemi Brox, Ana Sofia Pais, Naoko Mato, J.M. Cabezas Agrícola, Marta Diéguez, Lucia Díaz, Pilar Monge, Carolina Gándara, Anna Casteràs, Alejandro García‐Álvarez, André Vitor Protázio Garcia
Pubblicazione 2025Artigo
Strumenti per la ricerca:
Soggetti correlati
Internal medicine
Medicine
Oncology
Cancer
Immunotherapy
Clinical trial
Nivolumab
Renal cell carcinoma
Clinical endpoint
Neuroendocrine tumors
Cancer research
Lenvatinib
Pembrolizumab
Angiogenesis
Biology
Durvalumab
Gastroenterology
Phases of clinical research
Receptor
Sunitinib
Thyroid cancer
Adverse effect
Chemotherapy
Subgroup analysis
Surgery
Atezolizumab
Bioinformatics
Cabozantinib
Clear cell renal cell carcinoma
Cohort